



Defining and Grading an Obstructive Ventilatory Impairment: American Thoracic Society/ European Respiratory Society Interpretive Strategies of 2005 Versus 2022

Balsam Barkous ^{a*}, Khoulood Kchaou ^{a,b},
Chaima Briki ^a, Sirine Jamli ^a
and Saloua Ben Khamsa Jameleddine ^{a,b}

^a Department of Pulmonary Function Tests of Abderrahmen Mami Pneumology and Phthisiology Hospital, Ariana, Tunisia

^b Laboratory of Physiopathology, Food and Biomolecules (LR-17-ES-03), Technology Center of Sidi Thabet, University of Manouba, Tunis, Tunisia.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/AJMAH/2024/v22i2984

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/112813>

Original Research Article

Received: 02/12/2023

Accepted: 07/02/2024

Published: 13/02/2024

ABSTRACT

Background: The American Thoracic Society (ATS) and the European Respiratory Society (ERS) have issued several updates to their guidelines for lung function testing between 2005 and 2022.

Objective: We aimed to compare ATS/ERS recommendations for 2005(R1) and 2022(R2) in defining Obstructive Ventilatory Impairment (OVI) and in classifying its severity.

*Corresponding author: E-mail: balsam.barkous@gmail.com;

Patients and Methods: It was a retrospective comparative study including 1129 patients. All patients underwent spirometry with measurement of Forced Expiratory Volume in 1 second (FEV₁) and Forced Vital Capacity (FVC). An OVI was considered according to R1 when FEV₁/FVC ratio is under the Lower Limit of Normal (LLN) and when the z-score of FEV₁/FVC ratio is under -1.645 according to R2. For the severity levels of airflow obstruction: ATS/ERS previously recommended the use of percent predicted FEV₁ with 5 levels using cut values of 70%, 60%, 50% and 35%. Recently updated for z-scores with cut values of -2, -2.5 and -4. Mean age was 54.23±19.23 years.

Results: For defining an OVI, both definitions were comparable (529 patients with OVI). For the severity classification, the following proportions were assessed: 151 mild, 86 moderate, 84 moderately severe, 133 severe and 75 very severe vs 148 mild, 238 moderate, 76 severe and 67 cases having a normal FEV₁ (z-score of FEV₁ above -1.645), which were classified as mild according to R1. Mild OVI(R2) were distributed according to R1 into 74 mild, 51 moderate, 16 moderately severe and 7 severe. Moderate OVI (R2) were dispatched using R1 to 10 mild, 34 moderate, 66 moderately severe, 103 severe and 25 very severe. Severe OVI(R2) were classified as 1 moderate, 2 moderately severe, 23 severe and 50 very severe.

Conclusion: ATS/ERS new and previous recommendations seem to be comparable in defining OVI. However, discrepancies were assessed in classifying its severity.

Keywords: Physiology; respiratory function test; pulmonary disease; spirometry; forced expiratory volume; vital capacity.

ABBREVIATIONS

ATS/ERS : American Thoracic Society/ European Respiratory Society

C1 : Class 1

C2 : Class 2

C3 : Class 3

C4 : Class 4

COPD : Chronic Obstructive Pulmonary Disease

FEV₁ : Forced Expiratory Volume in 1 second

FVC : Forced Vital Capacity

GLI : Global Lung function Initiative

LLN : Lower Limit of Normal

OVD : Obstructive Ventilatory Disease

PFTs : Pulmonary Function Tests

R1 : ATS/ERS Recommendations of 2005

R2 : ATS/ERS Recommendations of 2022

SD : Standard Deviation

1. INTRODUCTION

Pulmonary function tests (PFTs) have played a crucial role in the screening, diagnosis and management of respiratory diseases [1,2]. In order to improve the quality control and interpretation of PFTs, a series of technical standardizations have been published by the American Thoracic Society (ATS) and European Respiratory Society (ERS). The ATS/ERS have issued several updates to their guidelines for lung function testing between 2005 and 2022 [3,4]. Interpretation of PFTs is usually based on comparisons of data measured in a patient with

reference (predicted) values based on healthy subjects with the same anthropometric data (e.g. sex, age and height) and where relevant ethnic characteristics of the patient being tested [3]. It is accepted that a diagnosis of airflow obstruction should be based on an abnormally low ratio of the Forced Expiratory Volume in 1 second (FEV₁) and Forced Vital Capacity (FVC) [5]. In 2005, the ATS/ERS have recommended the use of Lower Limit of Normal (LLN) in interpreting spirometry which is defined as the 5th percentile of a normal population [6]. In practice, the LLN of each spirometric data is obtained by the subtraction of '1.64 × residual standard deviation (SD)' from the predicted value [7]. In fact, an Obstructive Ventilatory Impairment (OVI) is defined when FEV₁/FVC ratio is under the LLN. However, the new ATS/ERS recommendations of 2022 consider the LLN as a z-score lower than '-1.64'. The Z-score is the signed number of Standard Deviations (SD) by which the value of a measured spirometric data differs from the mean value of what is being predicted [8]. Comparing z-score and LLN in lung function testing is important because they provide different information about the test results. Z-score measures how far a result is from the mean value, while LLN is a cut-off value that separates normal from abnormal results. Z-score is independent of age, height and sex, while LLN is age-dependent [9]. Severity levels of OVI differs between previous and new recommendations. It was previously based on percent predicted value of FEV₁ [6]. However, the latest ATS/ERS recommendations consider the use of FEV₁ z-

score to classify an OVI [4]. To the best of the authors' knowledge, there are limited data about making a comparison between the two recommendations. Therefore, we aimed to compare ATS/ERS recommendations for 2005 (R1) and 2022 (R2) in defining an OVI and in classifying its severity.

2. PATIENTS AND METHODS

2.1 Study Design

A retrospective comparative study was carried out within the Department of Functional Respiratory Explorations at Abderrahmane Mami Hospital, situated in Ariana, Tunisia. The investigation enrolled patients who sought consultations specifically for Pulmonary Function Tests (PFTs) throughout the period from January 2019 to March 2023.

The retrospective design of the study involved a comprehensive analysis of existing data derived from routine spirometry examinations. The utilization of this existing dataset facilitated a robust evaluation of the changes in interpreting spirometric data over the specified period, as outlined in the research objectives.

2.2 Study Population

Patients who underwent technically acceptable and reproducible spirometry maneuvers were included [10-12]. An OVI was defined according to ATS/ERS 2005 when the FEV₁/FVC ratio is under the LLN (Recommendation 1: R1) versus when the z-score of FEV₁/FVC ratio is under "-1.645" according to ATS/ERS 2022 (Recommendation 2: R2) [4]. The following severity classifications were applied: R1 which is based on percent predicted FEV₁ with 5 severity levels: mild (>70%), moderate (60-69%), moderately severe (50-59%), severe (35-49%) and very severe (<35%); R2 which considers the FEV₁ z-score with 3 severity levels: mild (-2.5 to -1.645), moderate (-2.51 to -4) and severe (<-4) [4]. A z-score is considered normal when it is above (-1.645). Then comparison of the number of patients obstructed according to R1 with the number obstructed using R2 was performed and identification of a common set of patients who were obstructed according to both prediction equations to compare the categorization of obstruction severity using both prediction models. For secondary analysis, the study population was divided into 4 ranges according to age: Class 1 (C1) for aged 5-18 years, Class 2

(C2) aged 18-40 years, Class 3 (C3) aged 40-65 years and Class 4 (C4) aged 65-89 years. Comparisons between different age categories were assessed. Then the total sample was divided into two groups based on severity: G1: severe obstruction vs G2: non-severe obstruction according to FEV₁% as well as z-score with cut-off values at 50% and -4, respectively.

2.3 Data Collection

Anthropometric data (age, sex, height and weight) were collected at the enrollment day for all subjects. The ethnic group considered for Tunisian individuals was Caucasian since spirometric data of 840 Tunisian healthy subjects were included into the Caucasian group [8].

2.4 Pulmonary Function Tests

Spirometry was performed for all patients according to ATS/ERS technical standards. Three key elements are needed to obtain high quality pulmonary function data: accurate and precise instrumentation, a subject capable of performing acceptable and reproducible measurements, and a motivated technologist to elicit maximum performance from the patient [11]. Predicted values and z-scores were derived for each subject in each dataset using prediction equations from the Global Lung Function Initiative (GLI-2012) [5].

2.5 Statistical Analysis

The Kolmogorov Smirnov test was used to analyze variables distribution. For continuous variables, results were expressed by their means \pm SD in case of normal distribution and equal variances. Otherwise, variables were expressed by their medians (1st -3rd quartiles). For categorical variables, frequencies were calculated for descriptive analysis. The Kappa test was used to assess the agreement level between R1 and R2 in defining an OVI. The chi-2 test was used to compare percentages of OVI and to assess its severity. Significance level was fixed at 0.05. Correlation Pearson test was used for variables with normal distribution, otherwise, the Spearman test was used.

3. RESULTS

A total of 1129 patients were included with male predominance (sex ratio at 1.58). A description of the total sample was assessed in Table 1. Among the entire sample, 70,5% of patient

experienced dyspnea, and dyspnea was classified according to the mMRC scale as follows: 25.9% mMRC 1; 32.1% mMRC 2; 9.7% mMRC 3 and 2.8% mMRC 4. The most prevalent reasons for consultation were asthma (38.9%) and Chronic Obstructive Pulmonary Disease (31.7%). There were correlations between FEV₁% and its z-score (r= 0.976), FVC and its z-score (r= 0.924) Fig. 1. An OVI was observed in 529 (46.8%) subjects according to both recommendations. The agreement level performed with Kappa test to compare the two reference values of LLN and z-score in defining an OVI has found a value of 1. Main etiologies of OVI were chronic obstructive pulmonary disease (COPD) (54.6%), asthma (32.4%) and other diagnosis such as bronchial dilatation, lung cancer and interstitial lung disease. For the classification of the disease severity, the following proportions were assessed: 28.5% mild, 16.2% moderate, 15.8% moderately severe, 25.1% severe and 14.1% very severe vs 28% mild, 45% moderate and 14.4% severe. It is crucial to notice that 12.7% of patient with OVI had a FEV₁ z-score above -1.645. This group of patients couldn't be classified among different severity levels using z-score. They were merged into the mild OVI according to R1. It is obvious that discrepancies consisted mainly in grading the severity of an OVI. Table 2 showed results of chi 2 test conducted to compare both classifications according to FEV₁ z-score and percent predicted FEV₁. In fact, mild OVI (R2) was distributed according to R1 into mild, moderate, moderately severe and severe OVI. Moderate OVI (R2) was dispatched using R1 to mild, moderate, moderately severe, severe and very severe OVI. Severe OVI (R2) was classified as severe and very severe OVI with R1. Table 3 showed the distribution of the study population according to different age classes (C1, C2, C3 and C4). By comparing R1 and R2 for the C1 (5-18 years), chi 2 test showed that both recommendations were perfectly similar (measurement of agreement with Kappa = 1) in defining an OVI (24 subjects, 24.2% had an OVI). However, there was a significant

difference in grading its severity (Pearson test <0.05). In fact, 7 mild OVI according to R2, were dispatched into 6 mild cases and 1 moderate case according to R1. Then, 5 moderate OVI (R2) were considered mild (1 subject), moderate (1 subject), moderately severe (2 subjects) and severe (1 subject) according to R1. Twelve cases of OVI while having a normal FEV₁ z-score were considered mild by considering the FEV₁%. For C 2 (18-40 years), both definitions overlapped in diagnosing OVI in 41 subjects (38.3%, Kappa = 1) and distinction of different severity classes was observed mainly in moderate OVI according to z-score. For C 3 (40-65 years), there was an agreement in terms of definition of OVI between R1 and R2 (52.5%, Kappa =1), but a significant difference in terms of grading OVI severity was observed. For C 4 (65-89 years), R1 and R2 were concordant in defining an OVI (61.6%, measure of agreement with Kappa= 1). Table 4 summarized differences in grading the severity of the OVI according to different age ranges. Table 5 showed that FEV₁ z-score underestimated the severity level of OVI. In fact, the chi 2 test concluded that there was no intersection between severe OVI with FEV₁ z-score and non-severe OVI with percent predict FEV₁, however, 150 patients with severe OVI using percent predicted FEV₁ were classified non-severe using FEV₁ z-score. By comparing G1 and G2 according to FEV₁%, there was a statistically significant difference in terms of age (64.31± 10.27 vs 51.44 ± 20.18vs, p<0.0001) and mMRC scale (1.94±1.02 vs 1.18±1.05, p<0.0001), respectively. As well as for FEV₁ z-score, there was a significant difference in age (57.21 ± 9.04 vs 53.99 ± 19.80, p<0.05) and mMRC scale (1.95±0.98 for G1 vs 1.29±1.08 for G2, p<0.05). The main result of this study was that the LLN and z-score of FEV₁/FVC ratio were similar in term of defining an OVI. However, the classification of the OVI using the FEV₁ z-score resulted in a change in the severity degrees established by the ATS/ERS recommendations in 2005 using the percent predicted FEV₁, particularly for the severe OVI.

Table 1. Description of the total sample

| | |
|----------------------------------|------------------------------|
| Age (years) | 54±19 |
| BMI (Kg/m ²) | 26.75±6.85 |
| FEV ₁ (L; %; z-score) | 2.08±0.88; 74±25; -1.61±1.54 |
| FVC (L; %; z-score) | 3.10±2.63; 85±21; -0.94±1.36 |
| Smoking (%) | 52 |
| Smoking intensity (Pack/years) | 25±34 |

Table 2. Concordance and discordance in grading the severity of an OVI using the FEV₁% vs the FEV₁ z-score

| | | Severity according to FEV ₁ z-score | | | | Total |
|--|-------------------|--|------|----------|--------|-------|
| | | Normal FEV ₁ z-score | Mild | Moderate | Severe | |
| Severity according to FEV ₁ % | Mild | 67 | 74 | 10 | 0 | 151 |
| | Moderate | 0 | 51 | 34 | 1 | 86 |
| | Moderately severe | 0 | 16 | 66 | 2 | 84 |
| | Severe | 0 | 7 | 103 | 23 | 133 |
| | Very severe | 0 | 0 | 25 | 50 | 75 |
| Total | | 67 | 148 | 238 | 76 | 529 |

OVI: Obstructive Ventilatory Impairment, FEV₁: Forced Expiratory Volume in 1 second

Table 3. Number of subjects grouped by age

| Age-class (years) | 5-18 | 18-40 | 40-65 | 65-89 |
|-------------------|------|-------|-------|-------|
| Subjects (%) | 9.6 | 10.3 | 46.8 | 33.3 |

Table 4. Comparison of the severity of OVI according to R1 vs R2 in different age classes

| | | Severity according to R2 | | | Total | |
|--------------------------|-------------------|---------------------------------|------|----------|-------|----|
| | | Normal FEV ₁ z-score | Mild | Moderate | | |
| Severity according to R1 | Mild | 12 | 6 | 1 | 19 | |
| | Moderate | 0 | 1 | 1 | 2 | |
| | Moderately severe | 0 | 0 | 2 | 2 | |
| | Severe | 0 | 0 | 1 | 1 | |
| Total | | 12 | 7 | 5 | 24 | |
| C2 | Mild | 10 | 14 | 2 | 0 | 26 |
| | Moderate | 0 | 0 | 8 | 0 | 8 |
| | Moderately severe | 0 | 0 | 3 | 0 | 3 |
| | Severe | 0 | 0 | 0 | 2 | 2 |
| | Very severe | 0 | 0 | 0 | 2 | 2 |
| Total | | 10 | 14 | 13 | 4 | 41 |

| | | Normal FEV ₁ z-score | Mild | Moderate | Severe | |
|--------------|--------------------------|---------------------------------|------|----------|--------|-------|
| C3 | Mild | 29 | 42 | 5 | 0 | 76 |
| | Moderate | 0 | 18 | 20 | 1 | 39 |
| | Moderately severe | 0 | 2 | 36 | 2 | 40 |
| | Severe | 0 | 6 | 38 | 16 | 60 |
| | Very severe | 0 | 0 | 1 | 38 | 39 |
| Total | | 29 | 68 | 100 | 57 | 254 |
| | | Normal FEV ₁ z-score | Mild | Moderate | Severe | Total |
| C4 | Mild | 16 | 12 | 2 | 0 | 30 |
| | Moderate | 0 | 32 | 5 | 0 | 37 |
| | Moderately severe | 0 | 14 | 26 | 0 | 40 |
| | Severe | 0 | 2 | 64 | 5 | 71 |
| | Very severe | 0 | 0 | 24 | 10 | 34 |
| Total | | 16 | 60 | 121 | 15 | 212 |

R1: ATS/ERS recommendations of 2005, R2: ATS/ERS recommendations of 2022, OVI: Obstructive Ventilatory Impairment

Table 5. Concordance and discordance between R1 and R2 in classifying severe OVI

| | | Severe OVI with z-score | | Total |
|---|------------|-------------------------|-----|-------|
| | | No | Yes | |
| Severe OVI with FEV₁% | No | 809 | 0 | 809 |
| | Yes | 150 | 72 | 222 |
| Total | | 959 | 72 | 1031 |

R1: ATS/ERS recommendations of 2005, R2: ATS/ERS recommendations of 2022, OVI: Obstructive Ventilatory Impairment, FEV₁: Forced Expiratory Volume in 1 second




Fig. 1. Correlations between spirometric parameters and their z-scores




Fig. 2. Correlations of FEV₁ and FVC with their z-scores considering different age-classes

4. DISCUSSION

The main outcome of this study is that the use of z-score in classifying OVI severity doesn't comply well with FEV₁%. In fact, only 3 stages (mild, moderate and severe) were identified using the z-score and there was a regrouping of different severity stages based on FEV₁%, especially for the moderate stage with z-score that had clustered all severity stages with FEV₁% from mild to very severe. On the other hand, the definition of an OVI using the z-score was in conformity with the use of the LLN. It is important to examine the potential effects of changes in the interpretative strategies of the ATS/ERS over time, and to assess similarities as well as discrepancies between reference values adopted in the interpretation of test results.

The present study results showed that ATS/ERS recommendations of 2005 as well as 2022 were matched in defining an OVI. In fact, percentage of patients having airflow limitation was similar according to both R1 and R2. As found by QUANJER et al who had included a larger sample size (17880 subjects) and concluded that ATS/ERS previous diagnostic criterion (LLN of FEV₁/FVC ratio) can be replaced with z-score maintaining the same interpretation of the test result [5]. Unlike percent of predicted, the z-score is free from bias due to age, height, sex and ethnic group, and is therefore particularly useful in defining the lower and upper limits of normal and in simplifying uniform interpretation of test results [13]. While the percent predicted of each outcome has a different cut-off, the z-score has the same cut-off of -1.645 for all outcomes across all ages, sex, ethnic groups and spirometric pulmonary function indices [14]. Consequently, an approach that reports spirometric values based on z-scores potentially provides an age-appropriate and clinically valid strategy for evaluating respiratory impairment [15]. Furthermore, the GLI task force released the GLI-2012 spirometric norms from data collected from 72,031 healthy individuals (26 countries) aged 3–95 years and Tunisia has participated with its reference values from 870 Tunisian adults aged ≥45 years and were included in the Caucasian group [16]. For the severity categorization, the z-score and FEV₁% were different in grading OVI. In fact, five severity levels were considered using FEV₁%, however only three stages were defined with z-score and still exist cases that couldn't be classified while having a normal FEV₁ z-score. Added to that, concordant classes with both definitions (mild,

moderate and severe OVI) are not exchangeable. For example, mild OVI (R2) combined mild, moderate, moderately severe and severe OVI with R1, moderate OVI (R2) included all severity levels using R1 and severe OVI (R2) merged moderate, moderately severe, severe and very severe OVI (R1). For the cases with normal FEV₁ z-score, they were considered mild using FEV₁%. These findings were on line with previous studies conducted by LINARES-PERDEMO et al, VUKOJA et al, and CHAIWONG et al, who have compared different reference equations used to define the LLN of FEV₁ and FEV₁/FVC ratio to define an OVI and grade its severity [17-19] and concluded that significant differences existed when classifying degree of lung function impairment with different predictive equations in patients with obstructive lung diseases [20]. The meaning of a low FEV₁/FVC ratio with a normal FEV₁ is unclear. It can be considered according to the ATS/ERS latest recommendations as "dysanapsis", which means an unequal growth of the airways and lung parenchyma [4]. This profile may be associated with the propensity for obstructive lung disease [21]. Several factors have been reported as associated with this pattern in healthy people including male sex, younger age and taller stature, with higher FVC above predicted [4]. Whether this pattern represents airflow obstruction will depend on the prior probability of obstructive disease and possibly on the results of additional tests, such as bronchodilator responsiveness, gas exchange evaluation and measurement of muscle strength or exercise testing [4]. By considering different age classes, R1 and R2 were perfectly similar in diagnosing OVI for all age classes. For the OVI classification, discrepancies were found in all age categories but less for C4, where OVI was nearly classified with both recommendations. In fact, mild OVI (R2) has been remained mild (R1), moderate OVI (R2) was classified as mild, moderate and moderately severe (R1), severe OVI (R2) was classified as severe and very severe (R1). It was demonstrated in this study that FEV₁% overestimates the determination of severe obstruction compared to z-score FEV₁ and this finding has been also supported by Tejero et al who had found that the adjustment of FEV₁ using its z-score underestimated the severity of the airflow limitation in individuals older than age 60 [22]. Previous studies have shown that spirometric data such as FEV₁ could be a good predictor of survival [23-26]. Thus, FEV₁ z-score could be used to determine the association with objective outcomes such as

mortality. The previously recommended severity levels for airflow obstruction considered percent predicted FEV₁ with 5 levels. However, this severity scale was then adapted for z-scores considering 3 levels. The new ATS/ERS standardization for interpretative strategies of pulmonary function tests have reported that the risk of mortality is associated with severity levels using z-score. In fact, z-score cut levels between -1.65 and -2.5 have little difference in risk of death and were therefore merged into a mild group. Individuals with z-score between -2.5 and -4 exhibit a moderate risk of mortality and these categories were therefore merged into the moderate category [4]. The purpose of our current study was not to determine the “best” spirometry prediction equation, but to inform clinicians that there are important differences essentially in grading airway obstruction between the ATS/ERS recommendations of 2005 and 2022. Thus, spirometry prediction equations should not be used interchangeably to define and categorize OVI for all patients, especially when longitudinal studies are needed. The GLI 2012 reference equations considered by ATS/ERS recommendations of 2022 are a huge step forward, providing a robust reference standard to rationalize the interpretation of spirometry results within and between populations worldwide.

4.1 Strengths and Limits

The strength of our study is that it had included a large database of 1129 patients with different ages (from 5 to 89 years), matching males and females, with several pathologies. Moreover, results were interesting and significant in showing discrepancies between different recommendations established by the ATS/ERS. One limit of this study is that it was a retrospective analysis of routinely obtained spirometric data of patients who have consulted our department during 2021-2023. Another limitation, is that there is no clear causal link between COVID19 infection and OVI since we have patients who consulted during the pandemic of COVID19.

5. CONCLUSION

In conclusion, this retrospective study scrutinized the evolution of lung function testing guidelines from 2005 to 2022, as set forth by the ATS/ERS. While the definitions for OVI remained consistent across the two guideline versions for 1129 patients, substantial disparities emerged in the

severity classification. The introduction of z-scores in the 2022 recommendations led to significant shifts in severity levels, particularly concerning the moderate and severe categories, compared to the earlier percent predicted FEV₁-based classification. This study underscores the crucial need for clinicians to grasp these nuanced distinctions, as they can significantly impact the interpretation and management of respiratory conditions based on pulmonary function testing.

CONCENT AND ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Wheatley JR. Spirometry: Key to the diagnosis of respiratory disorders. *Med J Aust.* 2017 Nov;207(10):422–3.
2. Miravittles M, de la Roza C, Morera J, Montemayor T, Gobartt E, Martín A et al. Chronic respiratory symptoms, spirometry and knowledge of COPD among general population. *Respir Med.* 2006 Nov;100(11):1973–80.
3. Pellegrino R. Interpretative strategies for lung function tests. *Eur Respir J.* 2005 Nov 1;26(5):948–68.
4. Stanojevic S, Kaminsky DA, Miller MR, Thompson B, Aliverti A, Barjaktarevic I et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. *Eur Respir J.* 2022 Jul;60(1):2101499.
5. Quanjer PH, Pretto JJ, Brazzale DJ, Boros PW. Grading the severity of airways obstruction: New wine in new bottles. *Eur Respir J.* 2014 Feb 1;43(2):505–12.
6. Miller MR. Standardisation of spirometry. *Eur Respir J.* 2005 Aug 1;26(2):319–38.
7. Kammoun R, Ghannouchi I, Rouatbi S, Ben Saad H. Defining and grading an obstructive ventilatory defect (OVD): 'FEV₁/FVC lower limit of normal (LLN) vs. Z-score' and 'FEV₁ percentage predicted (%pred) vs. Z-score'. *Libyan J Med.* 2018 Jan;13(1):1487751.

8. Ben Saad H, El Attar MN, Hadj Mabrouk K, Abdelaziz AB, Abdelghani A, Bousarssar M et al. The recent multi-ethnic global lung initiative 2012 (GLI2012) reference values don't reflect contemporary adult's North African spirometry. *Respir Med.* 2013 Dec;107(12):2000–8.
9. Hulo S, de Broucker V, Giovannelli J, Cherot-Kornobis N, Nève V, Sobaszek A et al. Global Lung Function Initiative reference equations better describe a middle-aged, healthy French population than the European Community for Steel and Coal values. *Eur Respir J.* 2016 Dec;48(6):1779–81.
10. Standardization of Spirometry—1987 Update. *Am Rev Respir Dis.* 1987 Nov;136(5):1285–98.
11. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement [Internet]. [cited 2023 Mar 1]. Available:<https://www.atsjournals.org/doi/pdf/10.1164/rccm.201908-1590ST?role=tab>
12. Quality Standards in Pulmonary Function Testing: Past, Present, Future [Internet]. [cited 2023 May 2]. Available:<https://www.atsjournals.org/doi/pdf/10.1513/AnnalsATS.201604-300ED?role=tab>
13. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH et al. Multi-ethnic reference values for spirometry for the 3–95 year age range: The global lung function 2012 equations. *Eur Respir J.* 2012 Dec;40(6):1324–43.
14. Stanojevic S, Wade A, Stocks J. Reference values for lung function: Past, present and future. *Eur Respir J.* 2010 Jul 1;36(1):12–9.
15. Vaz Fragoso CA, Gill TM, McAvay G, Van Ness PH, Yaggi HK, Concato J. Evaluating respiratory impairment in middle-aged persons using lambda-mu-sigma derived z-scores. *Respir Care.* 2011 Nov;56(11):1771–7.
16. Ben Saad H. Review of the current use of global lung function initiative norms for spirometry (GLI-2012) and static lung volumes (GLI-2021) in Great Arab Maghreb (GAM) countries and steps required to improve their utilization. *Libyan J Med.* 2022;17(1):2031596.
17. Linares-Perdomo O, Hegewald M, Collingridge DS, Blagev D, Jensen RL, Hankinson J, et al. Comparison of NHANES III and ERS/GLI 12 for airway obstruction classification and severity. *Eur Respir J.* 2016 Jul;48(1):133–41.
18. Vukoja M, Bokan A, Vujasinovic G, Kopitovic I. The Differences in Spirometry Predictive Equations in Classifying Presence and Degree of Lung Function Impairment: Which Suit Fits the Best? *Lung.* 2018 Feb;196(1):87–92.
19. Chaiwong W, Pothirat C, Liwsrisakun C, Phetsuk N, Bumroongkit C, Deesomchok A, et al. Effect of the Application of the Global Lung Initiative 2012 Spirometry Reference Equation on the Diagnosing and Classifying Degree of Airway Obstruction in Thai Adults Aged 40 to 80 Years Old. *Medicina (Mex).* 2019 Jun 21;55(6):295.
20. Sluga R, Smeele IJ, Lucas AE, Thoonen BP, Grootens-Stekelenburg JG, Heijdra YF et al. Impact of switching to new spirometric reference equations on severity staging of airflow obstruction in COPD: A cross-sectional observational study in primary care. *Prim Care Respir J J Gen Pract Airw Group.* 2014 Mar;23(1):85–91.
21. Forno E, Weiner DJ, Mullen J, Sawicki G, Kurland G, Han YY, et al. Obesity and Airway Dysanapsis in Children with and without Asthma. *Am J Respir Crit Care Med.* 2017 Feb 1;195(3):314–23.
22. Classification of Airflow Limitation Based on z-Score Underestimates Mortality in Patients with Chronic Obstructive Pulmonary Disease [Internet]. [cited 2023 Mar 15]. Available:<https://www.atsjournals.org/doi/pdf/10.1164/rccm.201611-2265OC?role=tab>
23. Schuñemann HJ, Dorn J, Grant BJB, Winkelstein W, Trevisan M. Pulmonary Function Is a Long-term Predictor of Mortality in the General Population. *Chest.* 2000 Sep;118(3):656–64.
24. Lange P. Spirometric findings as predictors of survival. *Thorax.* 2011 Jan 1;66(1):1–2.
25. Celli BR, Cote CG, Lareau SC, Meek PM. Predictors of Survival in COPD: More than

- Just the FEV1. *Respir Med.* 2008 Jun;102:S27–35.
26. Tockman MS, Pearson JD, Fleg JL, Metter EJ, Kao SY, Rampal KG et al. Rapid decline in FEV1. A new risk factor for coronary heart disease mortality. *Am J Respir Crit Care Med.* 1995 Feb;151(2):390–8.

© 2024 Barkous et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:

<https://www.sdiarticle5.com/review-history/112813>